Thread by @genghis_pon

1/ $TMDX results are positive, but FDA's job is to question things every step of the way.

In spirit of being informed / keeping a balanced view, below are some FDA concerns:

- Trial design (single-arm study)
- $TMDX's subjective definition of extended-criteria hearts
...

2/ - Extended-criteria hearts in EXPAND also include single-criterion >=4hr cross-clamp time, which actually make it somewhat overlap w/ PROCEED group

(i.e. imperfect definition extended-criteria heart)

3/ - 65% as questionable performance goal (b/c $TMDX defined goal after benchmarking w/ old studies that achieved 22.6%-32.0%, but those studies didn't use standard definition of PGD and don't know proportion of extended-criteria pop in those studies)
...

4/ - PROCEED II's LT survival results (not homerun overall outcomes, but I guess $TMDX shows low cardiac death)

Side note:
PROCEED is supplemental. Panel on EXPAND.
Good thing EXPAND is doing better than OCS PROCEED. Also, there are arguably worse-condition hearts in EXPAND.

5/ - Using FDA's Piecewise exponential model, FDA thinks EXPAND survival rate might drop to rates similar to PROCEED

- (i) Use of MCS (Mechanical Circulatory Support) & (ii) ICU stay length both higher in EXPAND than PROCEED's OCS / Control
*but again, these are worse hearts

6/ Ultimately, $TMDX beat the 65% benchmark in primary endpoint, but MUST keep balanced view.

FDA can question how data came about / whether it is valid.

This will ultimately depend on Panel. Waleed, Schroder and others at meeting need to be on A-game and crush it.

7/ I think it is crucial to emphasize that FDA Panel was never meant to be easy. This is normal.

As a rebuttal regarding single-arm trials, believe $TMDX will argue that it is unethical to randomize and use extended-criteria hearts w/ cold storage (can lead to death).

8/ PROCEED II should in theory also be supplemental information, given there is no control group for EXPAND.

Main focus is on EXPAND results, not PROCEED II, which used a different OCS Solution (HTK Custodiol, which is extracellular i.e., low potassium)

9/ Personally not my job to guess FDA decision (even CEO Waleed keeps repeating that he's not in the position to do so).

However, $TMDX's OCS Heart should bridge well into DCD Hearts which is a revolutionary unlock in supply.

10/ Leaving off w/ screenshot below. FDA mentions structure / setup of the trial, but let's not forget the worst survival rate is for unattended people on waitlists.

Believe $TMDX will give Tx surgeons more tools.
It will also give dying patients more options.